These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 12124821

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.
    J Clin Oncol; 2003 May 01; 21(9):1675-81. PubMed ID: 12721241
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.
    Cancer; 2006 Dec 15; 107(12):2745-51. PubMed ID: 17109443
    [Abstract] [Full Text] [Related]

  • 5. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group.
    J Clin Oncol; 2008 Mar 01; 26(7):1093-7. PubMed ID: 18195327
    [Abstract] [Full Text] [Related]

  • 6. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG.
    N Engl J Med; 2001 Jul 19; 345(3):159-64. PubMed ID: 11463009
    [Abstract] [Full Text] [Related]

  • 7. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB.
    Cancer; 2003 Jan 01; 97(1):1-11. PubMed ID: 12491499
    [Abstract] [Full Text] [Related]

  • 8. Surgical and financial implications of genetic counseling and requests for concurrent prophylactic mastectomy.
    Murphy RX, Adkinson JM, Namey T, Eid S, Bleznak A.
    Ann Plast Surg; 2010 May 01; 64(5):684-7. PubMed ID: 20395792
    [Abstract] [Full Text] [Related]

  • 9. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.
    Gynecol Oncol; 2005 May 01; 97(2):457-67. PubMed ID: 15863145
    [Abstract] [Full Text] [Related]

  • 10. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices.
    Geiger AM, Yu O, Herrinton LJ, Barlow WE, Harris EL, Rolnick S, Barton MB, Elmore JG, Fletcher SW.
    Arch Intern Med; 2005 Mar 14; 165(5):516-20. PubMed ID: 15767526
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?
    Leunen K, Drijkoningen M, Neven P, Christiaens MR, Van Ongeval C, Legius E, Amant F, Berteloot P, Vergote I.
    Breast Cancer Res Treat; 2008 Jan 14; 107(1):79-86. PubMed ID: 17431765
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH.
    Obstet Gynecol; 2006 Sep 14; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [Abstract] [Full Text] [Related]

  • 14. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy.
    Metcalfe KA, Esplen MJ, Goel V, Narod SA.
    Psychooncology; 2004 Jan 14; 13(1):14-25. PubMed ID: 14745742
    [Abstract] [Full Text] [Related]

  • 15. Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.
    McQuirter M, Castiglia LL, Loiselle CG, Wong N.
    Oncol Nurs Forum; 2010 May 14; 37(3):313-20. PubMed ID: 20439215
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction.
    Rueth NM, McMahon M, Arrington AK, Swenson K, Leach J, Tuttle TM.
    Ann Surg Oncol; 2011 Sep 14; 18(9):2515-20. PubMed ID: 21424371
    [Abstract] [Full Text] [Related]

  • 18. Prophylactic mastectomy in high risk patients: a practice-based review of the indications. Do we follow guidelines?
    Hoover DJ, Paragi PR, Santoro E, Schafer S, Chamberlain RS.
    Breast Dis; 2010 Sep 14; 31(1):19-27. PubMed ID: 20519802
    [Abstract] [Full Text] [Related]

  • 19. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
    Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L, Offit K.
    Cancer; 2005 Jan 01; 103(1):44-51. PubMed ID: 15558796
    [Abstract] [Full Text] [Related]

  • 20. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ, Fuhrman GM, Mauterer L, Bolton JS, Superneau DW.
    Breast J; 2004 Jan 01; 10(6):475-80. PubMed ID: 15569201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.